Faeth Therapeutics, Inc.
FTH
$32.34
$3.7913.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 177.93% | 115.25% | -13.10% | -18.49% | -16.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 619.68% | 514.56% | -29.61% | -24.56% | -15.25% |
| Operating Income | -619.68% | -514.56% | 29.61% | 24.56% | 15.25% |
| Income Before Tax | -628.96% | -535.43% | 30.08% | 19.00% | 9.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -628.96% | -535.43% | 30.08% | 19.00% | 9.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -628.96% | -535.43% | 30.08% | 19.00% | 9.60% |
| EBIT | -619.68% | -514.56% | 29.61% | 24.56% | 15.25% |
| EBITDA | -638.87% | -535.69% | 27.00% | 22.78% | 14.02% |
| EPS Basic | -564.76% | -518.30% | 30.35% | 19.40% | 9.68% |
| Normalized Basic EPS | -574.34% | -526.58% | 27.89% | 21.77% | 12.19% |
| EPS Diluted | -564.76% | -518.30% | 30.35% | 19.40% | 9.68% |
| Normalized Diluted EPS | -574.34% | -526.58% | 27.89% | 21.77% | 12.19% |
| Average Basic Shares Outstanding | 87.87% | 0.97% | 0.40% | 0.51% | 0.07% |
| Average Diluted Shares Outstanding | 87.87% | 0.97% | 0.40% | 0.51% | 0.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |